Pembrolizumab Plus Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma. (2023). Molecular Medicine Communications, 3(02), 89-92. https://doi.org/10.55627/mmc.003.02.0461